Cell-resolved transcriptomics separates the components of a pathway- wide PI3K–AKT response in dilated cardiomyopathy: the AKT1 change localizes to cardiomyocytes, the PIK3CA change peaks in fibroblasts
Using single-nucleus RNA sequencing to overcome the limitations of bulk tissue analysis, this study reveals that the PI3K–AKT pathway response in dilated cardiomyopathy comprises distinct, cell-type-specific components—specifically an AKT1 upregulation restricted to cardiomyocytes and a PIK3CA increase peaking in fibroblasts—rather than a unified, validated therapeutic target.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The heart is a muscle that must beat with relentless precision, but when it stretches and weakens, a condition known as dilated cardiomyopathy can take hold. This disease often leads to heart failure, a state where the organ can no longer pump enough blood to sustain the body. For decades, scientists have searched for the specific molecular switches that go wrong in this process, hoping to find a way to flip them back. One such switch is a signaling pathway called PI3K–AKT, a chain of chemical messages that cells use to grow, survive, and adapt to stress. In recent years, researchers have also looked to traditional herbal formulas, such as a Chinese remedy called Yangxin Decoction, which has been used for centuries to treat heart palpitations and anxiety. The hope was that this ancient mixture might work by turning off or turning on specific parts of the PI3K–AKT pathway. However, proving that a complex herbal mixture actually targets a specific molecule in a specific type of heart cell is incredibly difficult. The heart is not a single block of tissue; it is a crowded neighborhood of different cell types, including the muscle cells that do the pumping and the fibroblasts that provide structural support. When scientists look at the heart as a whole, the signals from these different neighbors get mixed together, often hiding the true story of what is happening inside the muscle cells themselves.
A team of researchers set out to untangle this confusion by using a modern technique called single-nucleus RNA sequencing. This method allows scientists to read the genetic activity of individual cells rather than averaging the results from a whole tissue sample. They began by taking the list of potential targets suggested by network pharmacology—a computational method that predicts which proteins a drug might bind to based on database records. This method had nominated several genes in the PI3K–AKT pathway as likely targets for Yangxin Decoction, with a particular focus on a gene called AKT1. The researchers then tested these predictions against real-world data from patients with dilated cardiomyopathy and viral myocarditis. They first looked at large datasets of heart tissue where all the cells were blended together. In these broad samples, the genes nominated by the herbal formula did not show a consistent pattern of change. The genes appeared to be no more active or inactive than any other random gene in the heart, and the specific target, AKT1, showed no significant change at all. This suggested that if the herbal remedy was working, its effect was being lost in the noise of the mixed tissue.
To find the hidden signal, the researchers separated the heart tissue into its individual cell populations. They examined the genetic activity of muscle cells, fibroblasts, immune cells, and others separately. When they looked specifically at the heart muscle cells, a clear picture emerged. In patients with dilated cardiomyopathy, the gene AKT1 was indeed more active, along with two other genes in the same pathway. However, this change was not happening everywhere. The increase in AKT1 was confined almost entirely to the muscle cells. In contrast, another gene in the same pathway, PIK3CA, showed a different pattern: it was active in many different types of cells, but it peaked in the fibroblasts, the cells that build the heart's structural framework. This distinction was crucial. It revealed that the heart's response to disease is not a single, uniform event. Instead, it is a complex mix where the muscle cells are reacting in one way while the supporting cells react in another. Because traditional methods average these signals, they had previously missed the specific change in the muscle cells.
The study then asked a deeper question: does this change in gene activity actually cause the disease, or is it just a reaction to it? To answer this, the researchers used genetic data to see if there were natural variations in human DNA that controlled the levels of these genes and were also linked to heart disease. They found no genetic evidence to support the idea that AKT1 is a primary driver of the disease. There were no genetic instruments strong enough to prove that changing the level of AKT1 would directly cause or prevent heart failure. Similarly, the genetic data did not support a causal link for the other genes in the pathway. The only genetic signal that appeared was weak and did not hold up to rigorous testing. This means that while the genes are certainly active and changing in the diseased heart, the study could not confirm that they are the root cause of the problem or that a drug targeting them would necessarily cure the disease.
The final conclusion is a careful refinement of what we know about this heart condition and the potential role of herbal medicine. The research confirms that the PI3K–AKT pathway is indeed engaged in dilated cardiomyopathy, but it is not a single, simple switch. It is a pathway-wide response where different parts of the pathway behave differently depending on which cell type is involved. The change in AKT1 is a specific event happening inside the muscle cells, while other parts of the pathway are active in the supporting cells. This finding explains why earlier studies looking at whole heart tissue failed to see the effect. However, the study also serves as a reality check. It shows that while the herbal formula Yangxin Decoction points toward these genes, the current evidence does not prove that the formula works by targeting them, nor does it prove that these genes are the cause of the disease. The researchers have mapped the terrain with greater precision, showing exactly where the activity is happening, but they have also shown that the path from this observation to a proven treatment is still long and requires further testing. The work moves the field from broad guesses to specific, cell-by-cell observations, providing a clearer target for future experiments to determine if these changes can be safely reversed to heal the heart.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.